866-997-4948(US-Canada Toll Free)

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

Published By :

GBI Research

Published Date : Apr 2018

Category :

Pharmaceutical

No. of Pages : 376 Pages

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.

These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.

Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.

Scope

- Which companies are the most active within the pipeline for cognitive impairment disorders?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 12
2.1 Cognitive Impairment Disorders Report Coverage 12
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 12
2.3 Dementia - Overview 12
2.4 Mild Cognitive Impairment - Overview 12
2.5 Alzheimer's Disease - Overview 12
3 Therapeutics Development 13
3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 13
3.2 Dementia 18
3.3 Mild Cognitive Impairment 30
3.4 Alzheimer's Disease 36
4 Therapeutics Assessment 90
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 90
4.2 Dementia 97
4.3 Mild Cognitive Impairment 108
4.4 Alzheimer's Disease 116
5 Companies Involved in Therapeutics Development 140
5.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 140
5.2 Dementia 148
5.3 Mild Cognitive Impairment 173
5.4 Alzheimer's Disease 182
6 Dormant Projects 286
6.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 286
6.2 Dementia 288
6.3 Mild Cognitive Impairment 292
6.4 Alzheimer's Disease 294
7 Discontinued Products 329
7.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 329
7.2 Dementia 330
7.3 Mild Cognitive Impairment 331
7.4 Alzheimer's Disease 332
8 Product Development Milestones 338
8.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 338
8.2 Dementia 339
8.3 Mild Cognitive Impairment 350
8.4 Alzheimer's Disease 357
9 Appendix 372
9.1 Methodology 372
9.2 Coverage 372
9.3 Secondary Research 372
9.4 Primary Research 372
9.5 Expert Panel Validation 372
9.6 Contact Us 372
9.7 Disclaimer 372

1.1 List of Tables
Table 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) 14
Table 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS) 16
Table 3: Products under Development by Companies Cognitive Impairment Associated With Schizophrenia (CIAS) 17
Table 4: Number of Products under Development for Dementia 19
Table 5: Number of Products under Development by Companies, Dementia 21
Table 6: Number of Products under Development by Universities/Institutes, Dementia 23
Table 7: Products under Development by Companies, Dementia 24
Table 8: Products under Development by Universities/Institutes, Dementia 30
Table 9: Number of Products under Development for Mild Cognitive Impairment 31
Table 10: Number of Products under Development by Companies, Mild Cognitive Impairment 33
Table 11: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment 34
Table 12: Products under Development by Companies, Mild Cognitive Impairment 35
Table 13: Products under Development by Universities/Institutes, Mild Cognitive Impairment 37
Table 14: Number of Products under Development for Alzheimer's Disease 38
Table 15: Number of Products under Development by Companies, Alzheimer's Disease 40
Table 16: Number of Products under Development by Universities/Institutes, Alzheimer's Disease 53
Table 17: Products under Development by Companies, Alzheimer's Disease 57
Table 18: Products under Development by Universities/Institutes, Alzheimer's Disease 82
Table 19: Number of Products by Stage and Target, Cognitive Impairment Associated With Schizophrenia (CIAS) 92
Table 20: Number of Products by Stage and Mechanism of Action, Cognitive Impairment Associated With Schizophrenia (CIAS) 94
Table 21: Number of Products by Stage and Route of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 96
Table 22: Number of Products by Stage and Molecule Type, Cognitive Impairment Associated With Schizophrenia (CIAS) 98
Table 23: Number of Products by Stage and Target, Dementia 100
Table 24: Number of Products by Stage and Mechanism of Action, Dementia 104
Table 25: Number of Products by Stage and Route of Administration, Dementia 107
Table 26: Number of Products by Stage and Molecule Type, Dementia 109
Table 27: Number of Products by Stage and Target, Mild Cognitive Impairment 111
Table 28: Number of Products by Stage and Mechanism of Action, Mild Cognitive Impairment 113
Table 29: Number of Products by Stage and Route of Administration, Mild Cognitive Impairment 115
Table 30: Number of Products by Stage and Molecule Type, Mild Cognitive Impairment 117
Table 31: Number of Products by Stage and Target, Alzheimer's Disease 119
Table 32: Number of Products by Stage and Mechanism of Action, Alzheimer's Disease 128
Table 33: Number of Products by Stage and Route of Administration, Alzheimer's Disease 138
Table 34: Number of Products by Stage and Molecule Type, Alzheimer's Disease 140
Table 35: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc 141
Table 36: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc 141
Table 37: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co 142
Table 38: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics 142
Table 39: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd 143
Table 40: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Co 143
Table 41: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd 144
Table 42: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck AS 144
Table 43: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Heptares Therapeutics Ltd 145
Table 44: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies Inc 145
Table 45: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL 146
Table 46: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc 146
Table 47: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sage Therapeutics Inc 147
Table 48: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB 147
Table 49: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL 148
Table 50: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Co Ltd 148
Table 51: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc 149
Table 52: Dementia - Pipeline by Acadia Pharmaceuticals Inc 149
Table 53: Dementia - Pipeline by Accera Inc 150
Table 54: Dementia - Pipeline by Acorda Therapeutics Inc 150
Table 55: Dementia - Pipeline by Actinogen Medical Ltd 151
Table 56: Dementia - Pipeline by Adamas Pharmaceuticals Inc 151
Table 57: Dementia - Pipeline by AgeneBio Inc 152
Table 58: Dementia - Pipeline by Alector LLC 152
Table 59: Dementia - Pipeline by Allergan Plc 153
Table 60: Dementia - Pipeline by Anavex Life Sciences Corp 153
Table 61: Dementia - Pipeline by Asceneuron SA 154
Table 62: Dementia - Pipeline by Axon Neuroscience SE 154
Table 63: Dementia - Pipeline by Axovant Sciences Ltd 155

1.2 List of Figures
Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) 14
Figure 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS) 15
Figure 3: Number of Products under Development for Dementia 19
Figure 4: Number of Products under Development by Companies, Dementia 20
Figure 5: Number of Products under Development by Universities/Institutes, Dementia 23
Figure 6: Number of Products under Development for Mild Cognitive Impairment 31
Figure 7: Number of Products under Development by Companies, Mild Cognitive Impairment 32
Figure 8: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment 34
Figure 9: Number of Products under Development for Alzheimer's Disease 37
Figure 10: Number of Products under Development by Companies, Alzheimer's Disease 39
Figure 11: Number of Products under Development by Universities/Institutes, Alzheimer's Disease 53
Figure 12: Number of Products by Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS) 91
Figure 13: Number of Products by Stage and Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS) 91
Figure 14: Number of Products by Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS) 93
Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS) 93
Figure 16: Number of Products by Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 95
Figure 17: Number of Products by Stage and Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 95
Figure 18: Number of Products by Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS) 97
Figure 19: Number of Products by Stage and Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS) 97
Figure 20: Number of Products by Top 10 Targets, Dementia 98
Figure 21: Number of Products by Stage and Top 10 Targets, Dementia 99
Figure 22: Number of Products by Top 10 Mechanism of Actions, Dementia 103
Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Dementia 103
Figure 24: Number of Products by Top 10 Routes of Administration, Dementia 106
Figure 25: Number of Products by Stage and Top 10 Routes of Administration, Dementia 106
Figure 26: Number of Products by Top 10 Molecule Types, Dementia 108
Figure 27: Number of Products by Stage and Top 10 Molecule Types, Dementia 108
Figure 28: Number of Products by Top 10 Targets, Mild Cognitive Impairment 109
Figure 29: Number of Products by Stage and Top 10 Targets, Mild Cognitive Impairment 110
Figure 30: Number of Products by Top 10 Mechanism of Actions, Mild Cognitive Impairment 112
Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Mild Cognitive Impairment 112
Figure 32: Number of Products by Routes of Administration, Mild Cognitive Impairment 114
Figure 33: Number of Products by Stage and Routes of Administration, Mild Cognitive Impairment 114
Figure 34: Number of Products by Molecule Types, Mild Cognitive Impairment 116
Figure 35: Number of Products by Stage and Molecule Types, Mild Cognitive Impairment 116
Figure 36: Number of Products by Top 10 Targets, Alzheimer's Disease 117
Figure 37: Number of Products by Stage and Top 10 Targets, Alzheimer's Disease 118
Figure 38: Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease 127
Figure 39: Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease 127
Figure 40: Number of Products by Top 10 Routes of Administration, Alzheimer's Disease 137
Figure 41: Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease 137
Figure 42: Number of Products by Top 10 Molecule Types, Alzheimer's Disease 139
Figure 43: Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease 139

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *